LONGEVITY / PEPTIDE CARD

SS-31 / Elamipretide

A mitochondria-targeted peptide known as elamipretide; FDA accelerated approval is limited to a specific Barth syndrome indication.

PEPTIDE CARDSS-31 / Elamipretide

Reviewed
August 7, 2026

Human evidence

3/5 · Narrow accelerated approval

U.S. FDAVerify current status

2026 WADANot specifically named

Inspect 2 sources

On this page

WHAT THE EVIDENCE SAYS

SS-31 / Elamipretide evidence summary.

SS-31 is no longer simply an unapproved research peptide: elamipretide now has one narrow accelerated-approval pathway, with confirmatory evidence still required.

Entity type
Synthetic peptideSource snapshot
August 7, 2026Record status
Sources attached

Do not overread this record

A rare-disease approval should not be generalized to longevity or performance claims.

01 / CLASSIFICATION

What is SS-31 / Elamipretide?

Entity typeSynthetic peptide

Research categoryLongevity

Known namesSS-31 / Elamipretide, Elamipretide, Forzinity

Editorial unitOne molecule or defined product record

Names, fragments, salts, formulations, routes, and branded products are kept distinct whenever transferring evidence would change the conclusion.

Class: Mitochondrial and mitochondrial-targeted peptides Goal: Longevity & Mitochondria Goal: Redox & Skin Goal: Longevity Research

02 / EVIDENCE

SS-31 / Elamipretide human and preclinical evidence.

HUMAN

3/5 · Narrow accelerated approval

Elamipretide received accelerated approval for a rare-disease indication based on a small clinical program; confirmatory work continues.

PRECLINICAL

4/5 · Extensive mitochondrial research

A broad mitochondrial literature does not expand the approved indication beyond the label.

The five-point bars describe the maturity and depth of the evidence base. They do not score effectiveness, safety, or personal suitability.

03 / STATUS

SS-31 / Elamipretide FDA and sport status.

U.S. FDAFDA accelerated approval as Forzinity for Barth syndrome patients weighing at least 30 kg; other uses remain unapproved.

2026 WADANot specifically named in the 2026 List; athletes should verify current status.

Commercial accessPeptideAgent does not route unapproved research substances to sellers.

Status summaries are educational and time-sensitive. Consult current official labeling and anti-doping resources for a decision.

04 / RESEARCH AREAS

What is SS-31 / Elamipretide being studied for?

01Barth syndrome

02Mitochondrial cardiolipin

03Muscle strength

04Mitochondrial disease

05 / COMPARISONS

Compare SS-31 / Elamipretide.

MOTS-c vs SS-31Two mitochondrial peptides with sharply different clinical status.Epitalon vs SS-31A longevity research peptide compared with a molecule that has one rare-disease accelerated approval.

06 / LATEST & DEFINING SOURCES

SS-31 / Elamipretide primary and official sources.

FDA / 2025FDA grants accelerated approval to first treatment for Barth syndrome

U.S. FDA

FDA / 2025Forzinity prescribing information

U.S. FDA

07 / QUESTIONS

Questions about SS-31 / Elamipretide.

Start with identity, research, human evidence, approval, sport status, and the limits of the current record.

EvidenceWhat is the evidence for SS-31 / Elamipretide?

SS-31 is no longer simply an unapproved research peptide: elamipretide now has one narrow accelerated-approval pathway, with confirmatory evidence still required.

ResearchWhat is SS-31 / Elamipretide being studied for?

Current source-backed research areas include Barth syndrome, Mitochondrial cardiolipin, Muscle strength, Mitochondrial disease. These areas describe investigation, not established personal benefit.

FDA statusIs SS-31 / Elamipretide FDA approved?

Current U.S. status for SS-31 / Elamipretide: FDA accelerated approval as Forzinity for Barth syndrome patients weighing at least 30 kg; other uses remain unapproved.

Sport statusIs SS-31 / Elamipretide prohibited in sport?

Current sport-status snapshot for SS-31 / Elamipretide: Not specifically named in the 2026 List; athletes should verify current status.

Evidence limitsWhat are the main evidence limits for SS-31 / Elamipretide?

A rare-disease approval should not be generalized to longevity or performance claims.